DLD Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

DLD Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-25,000	Closed	-$1.89M	–	148
2021 Q1	$1.89M	Buy	+25,000	New	+$2.04M	0.05%	97
2020 Q2	–	Sell	-31,900	Closed	-$2.69M	–	73
2020 Q1	$2.69M	Buy	31,900 +9,900	+45%	+$853K	0.17%	51
2019 Q4	$1.86M	Buy	22,000 +16,000	+267%	+$1.21M	0.1%	63
2019 Q3	$404K	Sell	6,000 -4,500	-43%	-$347K	0.02%	71
2019 Q2	$900K	Buy	+10,500	New	+$898K	0.04%	73

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

DLD Asset Management's BMRN Position: Q2 2023 in Review

DLD Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2023, closing a stake of 38,436 shares — an estimated $3.74M sold.

DLD Asset Management first reported a position in BMRN in Q4 2018 and held it in 11 quarters. The position peaked at $3.74M in Q1 2023. 558 funds tracked by Wall St. Rank hold BMRN as of Q2 2023.

DLD Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
DLD Asset Management sold 38,436 BioMarin Pharmaceuticals shares in Q2 2023, an estimated $3.74M.
DLD Asset Management first reported a position in BioMarin Pharmaceuticals in Q4 2018 and held it in 11 quarters.
DLD Asset Management's BioMarin Pharmaceuticals position peaked at $3.74M in Q1 2023.
558 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2023.

Based on DLD Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.